Hollywood doctor treats COVID-19 patients with his brother’s miracle cocktail

A COVID-19 related preprint – that quickly disappeared and reappeared after being discussed on social media – was brought to my attention by Dr. Kevin C Klatt via Twitter.

This preprint, authored by Robert Huizenga, is called Dramatic clinical improvement in nine consecutive acutely ill elderly COVID-19 patients treated with a nicotinamide mononucleotide cocktail: A retrospective case series.

In the study, Dr. Huizenga describes nine COVID-19 patients whom he treated with a mixture containing nicotinamide mononucleotide (NMN).

Unfortunately, Robert Huizenga failed to disclose that this mixture is sold by a company founded by his brother, Joel Huizenga. He also treated these patients without the approval of an institutional review board (IRB).

Continue reading “Hollywood doctor treats COVID-19 patients with his brother’s miracle cocktail”

COVID-19, small RNAs, and conflicts of interest

Recently a paper published in Nucleic Acid Therapeutics, a Mary Liebert publication not to be confused with the more glamorous Nucleic Acid Research journal, was brought to my attention. It described the potential use of small RNAs as a therapeutic against SARS-CoV-2.

Alas, it is most memorable because of the alarmingly short time-to-acceptance, lack of references, and the omission of several conflicts of interest.

Continue reading “COVID-19, small RNAs, and conflicts of interest”

ISAC shares concerns about the Hydroxychloroquine and Azithromycin paper

The International Society of Antimicrobial Chemotherapy (ISAC) has shared concerns about the Gautret et al. paper published in its own journal. This paper, published under senior authorship of Didier Raoult from the IHU-Méditerranée Infection in Marseille, describes a small study that showed remarkable effects of Hydroxychloroquine and Azithromycin treatment in COVID-19 patients.

After world leaders and politicians started to tweet and endorse this study, many people pressured health officials to start treating COVID-19 patients with this regime, although the study was small and not yet confirmed by independent, larger, and better randomized other studies.

Several scientists and medical professionals, including myself, had concerns about how patients were assigned to each treatment group, how PCR results were reported, why patients with a poor outcome had been left out of the final results, and how this treatment could potentially result in serious side effects. I wrote about my concerns in this blogpost and on PubPeer.

Now, ISAC, who is overseeing the International Journal of Antimicrobial Agents, the journal that published this study, has joined in those concerns.

Continue reading “ISAC shares concerns about the Hydroxychloroquine and Azithromycin paper”

Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections

There has been a lot of excitement – and even a presidential tweet about a recent paper from the lab of Didier Raoult, an infectious disease specialist in Marseille, France. But although this study might offer a glimmer of hope, there are some serious problems with the paper too.

Continue reading “Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections”